The trial is a Phase 1 Single Dose PK Study in Adolescent Subjects with Fragile X syndrome
(FXS) or Angelman syndrome (AS).
- The primary objective of the study is to evaluate the pharmacokinetics (PK) of OV101
following a single 5 mg dose of OV101 in adolescents with FXS or AS.
- Secondary objectives are to determine the safety and tolerability of a single 5 mg dose
of OV101 in adolescents with FXS or AS.